Vandortuzumab vedotin: Difference between revisions

Latest revision as of 11:15, 15 February 2025

Overview[edit]

Vandortuzumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It combines a monoclonal antibody specific to a target antigen on cancer cells with a potent cytotoxic agent, monomethyl auristatin E (MMAE), linked via a protease-cleavable linker. This allows for targeted delivery of the cytotoxic agent to cancer cells, minimizing damage to normal tissues.

Mechanism of Action[edit]

Vandortuzumab vedotin targets the CD70 antigen, which is overexpressed in various malignancies, including certain types of lymphoma and renal cell carcinoma. Upon binding to CD70, the ADC is internalized by the cancer cell, where the linker is cleaved by lysosomal enzymes, releasing MMAE. MMAE then disrupts the microtubule network, leading to cell cycle arrest and apoptosis.

Development and Clinical Trials[edit]

Vandortuzumab vedotin has been evaluated in several clinical trials to assess its safety and efficacy. Early-phase trials have shown promising results in terms of tumor response rates and manageable toxicity profiles. Ongoing studies aim to further define its role in the treatment of CD70-positive malignancies.

Side Effects[edit]

Common side effects of vandortuzumab vedotin include peripheral neuropathy, fatigue, nausea, and myelosuppression. These side effects are consistent with those observed with other vedotin-based ADCs, due to the action of MMAE on dividing cells.

Related pages[edit]

@@ Line 1: / Line 1: @@
-== Vandortuzumab vedotin ==
+{{DISPLAYTITLE:Vandortuzumab vedotin}}
-'''Vandortuzumab vedotin''' is an investigational [[antibody-drug conjugate]] (ADC) designed for the treatment of [[cancer]]. It is composed of a monoclonal antibody targeting the protein [[CD70]], which is linked to the cytotoxic agent [[monomethyl auristatin E]] (MMAE) via a protease-cleavable linker. This ADC is being developed to deliver the cytotoxic drug directly to cancer cells expressing CD70, thereby minimizing systemic exposure and reducing side effects.
+==Overview==
+[[File:Vedotin_ADCs.svg|thumb|right|Diagram of vedotin antibody-drug conjugates]]
+'''Vandortuzumab vedotin''' is an [[antibody-drug conjugate]] (ADC) designed for the treatment of certain types of [[cancer]]. It combines a monoclonal [[antibody]] specific to a target antigen on cancer cells with a potent cytotoxic agent, [[monomethyl auristatin E]] (MMAE), linked via a protease-cleavable linker. This allows for targeted delivery of the cytotoxic agent to cancer cells, minimizing damage to normal tissues.
-=== Mechanism of Action ===
+==Mechanism of Action==
-Vandortuzumab vedotin works by specifically binding to CD70, a protein that is overexpressed in various types of cancer cells, including [[renal cell carcinoma]], [[non-Hodgkin lymphoma]], and [[glioblastoma]]. Upon binding to CD70, the ADC is internalized into the cancer cell, where the linker is cleaved by lysosomal enzymes, releasing MMAE. MMAE then disrupts the microtubule network within the cell, leading to cell cycle arrest and apoptosis.
+Vandortuzumab vedotin targets the [[CD70]] antigen, which is overexpressed in various malignancies, including certain types of [[lymphoma]] and [[renal cell carcinoma]]. Upon binding to CD70, the ADC is internalized by the cancer cell, where the linker is cleaved by lysosomal enzymes, releasing MMAE. MMAE then disrupts the [[microtubule]] network, leading to cell cycle arrest and apoptosis.
-=== Development and Clinical Trials ===
+==Development and Clinical Trials==
-Vandortuzumab vedotin is being developed by [[Seattle Genetics]], a biotechnology company known for its work in ADCs. The drug has undergone several phases of clinical trials to evaluate its safety, tolerability, and efficacy in patients with CD70-positive cancers. Early-phase trials have shown promising results, with manageable side effects and evidence of anti-tumor activity.
+Vandortuzumab vedotin has been evaluated in several [[clinical trials]] to assess its safety and efficacy. Early-phase trials have shown promising results in terms of tumor response rates and manageable toxicity profiles. Ongoing studies aim to further define its role in the treatment of CD70-positive malignancies.
-=== Side Effects ===
+==Side Effects==
-As with other ADCs, the side effects of vandortuzumab vedotin are primarily related to the cytotoxic payload. Common adverse effects include [[neutropenia]], [[peripheral neuropathy]], and fatigue. The safety profile is continuously monitored in clinical trials to ensure that the benefits outweigh the risks.
+Common side effects of vandortuzumab vedotin include [[peripheral neuropathy]], fatigue, nausea, and [[myelosuppression]]. These side effects are consistent with those observed with other vedotin-based ADCs, due to the action of MMAE on dividing cells.
-=== Future Directions ===
+==Related pages==
-Research is ongoing to explore the full potential of vandortuzumab vedotin in various cancer types. Combination therapies with other anticancer agents are also being investigated to enhance its efficacy. The development of biomarkers to predict response to treatment is another area of active research.
-== Related Pages ==
 * [[Antibody-drug conjugate]]
 * [[Monomethyl auristatin E]]
 * [[CD70]]
-* [[Seattle Genetics]]
+* [[Cancer treatment]]
-== References ==
-{{Reflist}}
-[[File:Vedotin_ADCs.svg|thumb|right|Diagram of vedotin-based ADCs, showing the structure of the linker and payload.]]
-[[Category:Experimental cancer drugs]]
 [[Category:Antibody-drug conjugates]]
+[[Category:Cancer treatments]]